Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases

Table 1 Summary of treatment criteria for chronic hepatitis B

	HBeAg+; HBV DNA (IU/mL)	HBeAg+; ALT (IU/L)	HBeAg–; HBV DNA (IU/mL)	HBeAg–; ALT (IU/L)	Cirrhosis
EASL[15]	≥ 2000	> ULN and/or at least moderate liver necro-inflammation or fibrosis	≥ 2000	> × ULN or significant histological disease	HBV-DNA detectable
	≥ 20000	> 2 × ULN or irrespective of fibrosis	≥ 20,000	> 2 × ULN irrespective of fibrosis
APASL[16]	≥ 20000	> 2 × ULN or significant histological disease	≥ 2000	> 2 × ULN or significant histological disease	HBV-DNA detectable
AASLD[17]	> 20000	> 2 × ULN or significant histological disease	≥ 2000	> 2 × ULN or significant histological disease	HBV-DNA detectable
JSG[18]	≥ 2000	> ULN	≥ 2000	> ULN	HBV-DNA detectable

AASLD: American Association for the Study of Liver Disease; ALT: Alanine aminotransferase; APASL: Asian-Pacific Association for the Study of the Liver; EASL: European Association for the Study of Liver Disease; HBeAg: Hepatitis B e-antigen; HBV: Hepatitis B virus; JSG: Japanese Society of Hepatology; ULN: Upper limit of normal.